Argyro Repa

Overview

Explore the profile of Argyro Repa including associated specialties, affiliations and a list of published articles.

Snapshot

Articles 36

Citations 422

Followers 0

Related Specialties

Rheumatology

General Medicine

Psychology

Top 10 Co-Authors

Prodromos Sidiropoulos

George Bertsias

Antonis Fanouriakis

Nestor Avgoustidis

Dimitrios T Boumpas

Irini Gergianaki

Myrto Nikoloudaki

Irini Flouri

Sofia Pitsigavdaki

Nikolaos Kougkas

Published In

Ann Rheum Dis

Mediterr J Rheumatol

Rheumatology (Oxford)

J Clin Med

Arthritis Res Ther

Affiliations

Soon will be listed here.

Recent Articles

Combination of clinical factors predicts successful glucocorticoid withdrawal in systemic lupus erythematosus (SLE): results from a multicentre, retrospective cohort study

Katechis S, Pitsigavdaki S, Nikoloudaki M, Silvagni E, Repa A, Marangoni A, et al.

RMD Open . 2025 Jan; 11(1). PMID: 39762120

Objective: Glucocorticoid (GC) tapering and withdrawal to reduce damage represents a key aspect of the European Alliance of Associations for Rheumatology (EULAR) SLE recommendations. However, optimal strategies for relapse-free GC...

Anifrolumab for systemic lupus erythematosus with multi-refractory skin disease: A case series of 18 patients

Flouda S, Emmanouilidou E, Karamanakos A, Koumaki D, Katsifis-Nezis D, Repa A, et al.

Lupus . 2024 Aug; 33(11):1248-1253. PMID: 39098049

Objective: Skin involvement is common in systemic lupus erythematosus (SLE), but may be resistant to conventional treatment. We sought to evaluate the efficacy of anifrolumab (ANI) in refractory cutaneous manifestations...

Comorbidities Burden and Implementation of the Treat-to-Target Strategy in Predicting Real-World Patient Outcomes in Spondyloarthritides

Flouri I, Repa A, Avgoustidis N, Pitsigavdaki S, Pateromichelaki K, Marolachaki E, et al.

Mediterr J Rheumatol . 2024 Jan; 34(4):581-587. PMID: 38282943

New biologic and small molecule targeted agents have expanded the armamentarium of Spondyloarthritides (SpA), allowing more therapeutic options for patients who do not respond to therapy. The implementation of the...

Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with 'difficult to treat' rheumatoid arthritis

Bertsias A, Flouri I, Repa A, Avgoustidis N, Kalogiannaki E, Pitsigavdaki S, et al.

RMD Open . 2024 Jan; 10(1). PMID: 38242549

Background: Characterisation of the long-term outcome of patients with 'difficult to treat' (D2T) rheumatoid arthritis and factors contributing to its evolution are unknown. Herein, we explored the heterogeneity and contributing...

Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free...

Pitsigavdaki S, Nikoloudaki M, Garantziotis P, Silvagni E, Repa A, Marangoni A, et al.

Ann Rheum Dis . 2024 Jan; 83(4):464-474. PMID: 38233103

Objectives: Treatment targets in systemic lupus erythematosus (SLE) have been validated in unselected-in terms of severity-cohorts, which limits their generalisability. We assessed remission (Definition of Remission in SLE (DORIS)) and...

A Peripheral Blood Signature of Increased Th1 and Myeloid Cells Combined with Serum Inflammatory Mediators Is Associated with Response to Abatacept in Rheumatoid Arthritis Patients

Goutakoli P, Papadaki G, Repa A, Avgoustidis N, Kalogiannaki E, Flouri I, et al.

Cells . 2023 Dec; 12(24). PMID: 38132128

Abatacept (CTLA4-Ig)-a monoclonal antibody which restricts T cell activation-is an effective treatment for rheumatoid arthritis (RA). Nevertheless, only 50% of RA patients attain clinical responses, while predictors of response are...

Progressive Multifocal Leukoencephalopathy in Systemic Lupus Erythematosus: A Consequence of Patient-Intrinsic or -Extrinsic Factors?

Emmanouilidou E, Kosmara D, Papadaki E, Mastorodemos V, Constantoulakis P, Repa A, et al.

J Clin Med . 2023 Nov; 12(21). PMID: 37959410

Progressive multifocal leukoencephalopathy (PML) is a severe demyelinating disease of the central nervous system (CNS) caused by reactivation of the polyomavirus JC (JCV) typically in immunocompromised individuals. The risk of...

Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study

Flouri I, Goutakoli P, Repa A, Bertsias A, Avgoustidis N, Eskitzis A, et al.

Rheumatol Int . 2023 Oct; 44(2):249-261. PMID: 37815625

To characterize disease activity trajectories and compare long-term drug retention between rheumatoid (RA) and spondylarthritis (SpA) patients initiating tumor necrosis factor inhibitor (TNFi) treatment (etanercept). Prospective observational study of RA,...

Patterns and factors associated with pneumococcal vaccination in a prospective cohort of 1,697 patients with rheumatoid arthritis

Thomas K, Lazarini A, Kaltsonoudis E, Voulgari P, Drosos A, Repa A, et al.

Front Med (Lausanne) . 2023 Jan; 9:1039464. PMID: 36698802

Introduction: Patients with rheumatoid arthritis (RA) are at increased risk for serious infections. Pneumococcal vaccination is among the most important preventive measures, however, vaccine uptake is suboptimal. We explored the...

10.

Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study

Nikoloudaki M, Nikolopoulos D, Koutsoviti S, Flouri I, Kapsala N, Repa A, et al.

Front Immunol . 2023 Jan; 13:1074044. PMID: 36685524

Objective: To obtain real-world data on outcomes of belimumab treatment and respective prognostic factors in patients with systemic lupus erythematosus (SLE). Methods: Observational study of 188 active SLE patients (median...